Table 5.
Efficacy of 400 mg sofosbuvir QD + PegIFNα/RBV for 12w.
| Cirrhosis | Prior treatment | SVR12 rate |
Study and trial phase | Ref. | |||||
|---|---|---|---|---|---|---|---|---|---|
| GT-1 | GT-2 | GT-3 | GT-4 | GT-5 | GT-6 | ||||
| No cirrhosis |
Experienced | 100% (9/9) | 83.3% (10/12) | LONESTAR-2, phase 2 | Lawitz et al., 2015b | ||||
| Naïve | 100% (4/4) | 100% (7/7) | Electron, phase 2a | Gane et al., 2013a | |||||
| Naïve | 91.5% (43/47) | 93.3% (14/15) | 90% (9/10) | Phase 2a | Lawitz et al., 2013b | ||||
| Experienced | 78.8% (63/80) | Phase 2 | Pol et al., 2015 | ||||||
| Naïve | 87% (275/316) | 81.8% (9/11) | 100% (5/5) | ATOMIC, phase 2 | Kowdley et al., 2013 | ||||
| Naïve | 91.3% (219/240) | 100% (27/27) | 100% (1/1) | 100% (5/5) | NEUTRINO, phase 3 | Lawitz et al., 2013a | |||
| Naïve | 95.8% (68/71) | BOSON, phase 3 | Foster et al., 2015a | ||||||
| Experienced | 94.2% (49/52) | ||||||||
| Naïve | 100% (16/16) | ? | C-EDGE Head-2-Head, phase 3 |
Sperl et al., 2016 | |||||
| Experienced | 100% (1/1) | ? | |||||||
| Naïve | 100% (4/4) | HCV-TARGET, phase 4 | Feld et al., 2016a | ||||||
| Experienced | 75% (3/4) | ||||||||
| Naïve | 98.1% (252/257) | KULDS, real-world study |
Ogawa et al., 2016 |
||||||
| Experienced | 95.9% (95/99) | ||||||||
| Cirrhosis | Experienced | 92.9% (13/14) | 83.3% (10/12) | LONESTAR-2, phase 2 | Lawitz et al., 2015b | ||||
| Naïve | 91.3% (21/23) | BOSON, phase 3 | Foster et al., 2015a | ||||||
| Experienced | 93.8% (15/16) | 85.7% (30/35) | |||||||
| Naïve | 80.8% (42/52) | 0% (0/1) | 100% (1/1) | NEUTRINO, phase 3 | Lawitz et al., 2013a | ||||
| Naïve | 66.7% (2/3) | HCV-TARGET, phase 4 | Feld et al., 2016a | ||||||
| Experienced | 87.5% (7/8) | ||||||||
| Naïve | 95.6% (43/45) | KULDS, real-world study | Ogawa et al., 2016 | ||||||
| Experienced | 82.2% (37/45) | ||||||||
?: Question marks indicate that the data was unavailable in literature.